Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.34 |
| ▸ | PLD2 | O14939 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181669 | 1.00 | BIRC2 (0.47) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL190024 | 1.00 | BIRC2 (0.47) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL4033981 | 0.88 | BIRC2 (0.49) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL25224263 | 0.88 | BIRC2 (0.49) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL28621816 | 0.86 | BIRC2 (0.51) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL27957087 | 0.84 | BIRC2 (0.49) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL28120270 | 0.84 | BIRC2 (0.49) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL28048803 | 0.84 | BIRC2 (0.49) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL2422071 | 0.83 | BIRC2 (0.47) | BIRC2HRH4RENCHRNB2CHRNA3 | |
| SCHEMBL2418463 | 0.83 | BIRC2 (0.47) | BIRC2HRH4RENCHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150653-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | claimed |
| CN-115466259-A | Preparation method of KRAS G12C inhibitor sotoxib | 山东大学 | 2022-12-13 | — | — | CN | claimed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| CN-115151257-B | Novel compounds for the treatment of diseases associated with DUX4 expression | 因维戈疗法有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118317963-A | TRPML modulators, compositions thereof, and methods of use | 卡拉韦治疗公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302411-A | Therapeutic indazole compounds and methods of use thereof for the treatment of cancer | 基因泰克公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-114901663-B | Aromatic heterocyclic compounds and application thereof in medicines | 上海喆邺生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | BIRC2 3948/4885HRH4 4151/4885REN 1683/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | BIRC2 1446/4885HRH4 411/4885REN 2008/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | BIRC2 3948/4885HRH4 4151/4885REN 1683/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | BIRC2 2107/4885HRH4 1329/4885REN 2727/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | BIRC2 2715/4885HRH4 2270/4885REN 805/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | BIRC2 44/4885HRH4 4364/4885REN 2311/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | BIRC2 2594/4885HRH4 641/4885REN 748/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | BIRC2 875/4885HRH4 2899/4885REN 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.